21.06.2016
Evonik Industries AG DE000EVNK013
DGAP-News: Evonik Industries AG: Evonik increases the value of its innovation pipeline by half a billion euros
DGAP-News: Evonik Industries AG / Key word(s): Miscellaneous
Evonik Industries AG: Evonik increases the value of its innovation pipeline
by half a billion euros
21.06.2016 / 11:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Embargoed until: June 21, 2016, 11.00 a.m.
Evonik increases the value of its innovation pipeline by half a billion
euros
- Evonik innovation campaign bears fruit-innovative power considerably
enhanced
- In the medium term, Evonik aims for products and applications developed
in the past five years to account for over 16 percent of sales
- Growth fields should generate over EUR1 billion in additional sales by
2025
Evonik Industries is strengthening its innovative power. Last year, the
specialty chemicals company increased the value of its innovation pipeline
by half a billion euros. This now places the value of the pipeline in the
lower single-digit billion euro range-a figure that is expected to continue
growing over the next few years. At today's R&D press briefing in Essen,
Germany, Chairman of the Executive Board of Evonik Industries Klaus Engel
said: "Our innovation campaign is bearing fruit. The constant flow of new
products, applications, and business models is a major driver of profitable
growth at Evonik. Innovations are to make an even larger contribution to
sales and profit going forward." In the medium term, the Group aims for
products and applications developed in the past five years to account for
over 16 percent of sales. Currently, these constitute around 10 percent of
sales.
"It's an ambitious goal," said Evonik Chief Innovation Officer Ulrich
Küsthardt, "and we have taken additional steps in order to meet it." Evonik
has brought its innovation portfolio into focus, redefined its growth
fields, and taken the development of its innovation culture still further.
Küsthardt said, "We have a total of six growth fields, which we expect to
contribute over EUR1 billion in additional sales by the year 2025." These
fields are in highly attractive markets where Evonik can offer new products
and solutions in line with its core competencies. Examples here include
sustainable nutrition, healthcare solutions, and cosmetic solutions.
Reorganizing these growth fields goes hand in hand with focusing on the
innovation portfolio. The streamlined innovation portfolio now includes a
more significant portion of larger innovation projects, as well as those to
be carried out over the medium and long term. This will allow the company
to make more efficient use of resources.
Idea competitions and fostering entrepreneurship represent additional ways
of improving the culture of innovation.
The planned acquisition of the specialty additives business (the
Performance Materials Division) of US-based Air Products is likewise
expected to strengthen Evonik's innovative power in the field of specialty
additives. Air Products' specialty additives business employs excellent R&D
personnel and maintains a powerful R&D pipeline.
"We want to become one of the most innovative companies in the world," said
Küsthardt, underscoring the ambitions of the specialty chemicals company.
According to a Forsa survey, nearly 50 percent of those surveyed trust
Evonik to meet this goal over the medium term. Over 75 percent of those
surveyed see Evonik as an innovative company. Early this year, Evonik
contracted Forsa, an independent opinion research institute, to conduct the
survey among select target groups, such as customers, investors,
politicians, scientists, and employees.
R&D at Evonik 2015
R&D expenditures EUR434 million
R&D expenditures, 2010 - 2015 Average increase: 6%
per year
Rate of R&D investment 3.2 %
Portion of sales tied to products and applications
developed in the past five years Roughly 10%
Development of innovation pipeline value,
2014-2015 Increase of EUR500
million
Sales of patented products 57%
Number of new patent applications
submitted in 2015 Roughly 260
Portfolio of patents and patent
applications Over 25,000
Portfolio of pending and registered
trademarks Over 7,000
R&D employees Roughly 2,700
R&D sites 35
More information on the specifics of today's R&D press briefing can be
found in the following publications:
- Biodegradable composites: a significant advance in medical implant
technology
- Sustainability in aquaculture: Evonik turns salmon, shrimp, and other
marine animals into vegetarians
- Evonik commercializes biosurfactants
More information on biosurfactants is available in the current edition (No.
55) of "elements," Evonik's innovationmagazine.
For more information you can visit our website: http://corporate.evonik.de/
en/media/publications/elements/pages/default.aspx
Company information
Evonik, the creative industrial group from Germany, is one of the world
leaders
in specialty chemicals. Profitable growth and a sustained increase in the
value of the company form the heart of Evonik's corporate strategy. Its
activities focus on the key megatrends health, nutrition, resource
efficiency and globalization. Evonik benefits specifically from its
innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2015
more than 33,500 employees generated sales of around EUR13.5 billion and an
operating profit (adjusted EBITDA) of about EUR2.47 billion.
Disclaimer
In so far as forecasts or expectations are expressed in this Investor
Relations News or where our statements concern the future, these forecasts,
expectations or statements may involve known or unknown risks and
uncertainties. Actual results or developments may vary, depending on
changes in the operating environment. Neither Evonik Industries AG nor its
group companies assume an obligation to update the forecasts, expectations
or statements contained in this release.
Contact:
Tim Lange
Head of Investor Relations
Phone +49 201 177-3150
[email protected]
Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Telefax +49 201 177-3475
www.evonik.com
Supervisory Board
Dr. Werner Müller, Chairman
Executive Board
Dr. Klaus Engel, Chairman
Christian Kullmann, Deputy Chairman
Dr. Ralph Sven Kaufmann
Thomas Wessel
Ute Wolf
Registered office Essen
Registered court
Essen local court
Commercial registry B 19474
VAT ID no. DE 811160003
---------------------------------------------------------------------------
21.06.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone: +49 (0) 201 177-01
Fax: +49 (0) 201 177-3475
E-mail: [email protected]
Internet: www.evonik.com
ISIN: DE000EVNK013, XS0911405784
WKN: EVNK01, A1TM7T
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Hamburg, Hanover, Munich,
Stuttgart; Terminbörse EUREX; Luxemburg
End of News DGAP News Service
---------------------------------------------------------------------------
472817 21.06.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evonik Industries AG ISIN: DE000EVNK013 können Sie bei EQS abrufen
Chemie , EVNK01 , EVK , XETR:EVK